Knut Pettersson, Håkan Bergstrand
Index: Cardiovasc. Drug Rev. 21(2) , 119-32, (2003)
Full Text: HTML
Inflammatory processes in the arterial wall are important in atherogenesis. The present review discusses the development of DiNAC as a potential new treatment modality for atherosclerosis related diseases. DiNAC, N,N'-diacetyl-L-cystine, is the disulphide dimer of N-acetyl cysteine, NAC. It was selected as an immunomodulating drug candidate due to its ability to modify contact sensitivity/delayed type hypersensitivity (CS/DTH) reactions in vivo. Initial structure-activity relationship (SAR) studies indicated that an intact disulfide bridge was essential for this effect. Antioxidants, like probucol and some close analogs with two sulphurs in close proximity (but not disulphides), were also found to have similar effects on CS/DTH reactions. These antioxidants have antiatherosclerotic effects, while structurally related compounds without sulphurs do not. Therefore, it was hypothesized that DiNAC might also possess antiatherosclerotic effects. This was investigated in WHHL rabbits and mice. In both species, DiNAC had antiatherosclerotic activity similar to that of probucol. The effect of DiNAC was not due to an alteration of lipid metabolism. Impaired endothelium mediated relaxation is known to be associated with atherosclerosis. DiNAC was shown to reverse this process in WHHL rabbits with advanced atherosclerosis, probably due to an action on the vessel wall itself that is not related to the extent of atherosclerosis or to plasma lipid levels. Preliminary data from a clinical investigation in hypercholesterolemic subjects suggest that DiNAC is likely to have similar effects also in patients. Taken together, these findings suggest immunomodulation to be a potential new therapy for atherosclerosis related diseases. DiNAC may represent a new treatment modality for such diseases.
Structure | Name/CAS No. | Molecular Formula | Articles |
---|---|---|---|
![]() |
N,N'-Diacetyl-L-cystine
CAS:5545-17-5 |
C10H16N2O6S2 |
Influence of N,N'-diacetyl-L-cystine on D-galactosamine/lipo...
2004-10-01 [Yao Xue Xue Bao 39(10) , 782-6, (2004)] |
Immunomodulation with DiNAC-- a new approach to the treatmen...
2002-05-01 [Expert Opin. Investig. Drugs 11(5) , 717-20, (2002)] |
The new oral immunomodulating drug DiNAC induces brachial ar...
2008-01-01 [Atherosclerosis 196(1) , 275-82, (2008)] |
N,N'-Diacetyl-L-cystine-the disulfide dimer of N-acetylcyste...
1999-03-01 [J. Pharmacol. Exp. Ther. 288(3) , 1174-84, (1999)] |
Monitoring of the subtraction process in solid-phase represe...
2001-06-27 [Gene 271(2) , 183-92, (2001)] |
Home | MSDS/SDS Database Search | Journals | Product Classification | Biologically Active Compounds | Selling Leads | About Us | Disclaimer
Copyright © 2024 ChemSrc All Rights Reserved